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Abstract Immunotherapy is a sort of therapy in which
antibody or antigen administrates to the patient in order to
treat or reduce the severity of complications of disease.
This kind of treatment practiced in a wide variety of dis-
eases including infectious diseases, autoimmune disorders,
cancers and allergy. Successful and unsuccessful immu-
notherapeutic strategies have been practiced in variety of
parasitic infections. On the other hand parasites or parasite
antigens have also been considered for immunotherapy
against other diseases such as cancer, asthma and multiple
sclerosis. In this paper immunotherapy against common
parasitic infections, and also immunotherapy of cancer,
asthma and multiple sclerosis with parasites or parasite
antigens have been reviewed.
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Introduction
Immunotherapy, which is also called biotherapy, is defined
as uses of biological substances to regulate or adjust
responses of human or animal’s immune system to fulfill a
prophylactic and/or therapeutic goals. In immunotherapy,
immunomodulators or biological response regulators
interfere with immune system. Therefore, immunothera-
peutic agents can directly or indirectly raise bodie’s natural
defenses (Okwor and Uzonna 2009; Oldham 1988).
Currently two types of immunotherapy are mostly used.
The first type, which is called antibody based or passive
immunotherapy, is used for variety of diseases such as
cancer (Noguchi et al. 2013; Tse et al. 2014; Weiner et al.
2012), cryptosporidiosis (Crabb 1998; Fayer et al. 1990;
Riggs et al. 1994; Santı´n and Trout 2009) and malaria
(Schofield et al. 1993). Another type of immunotherapy is
antigen based or active immunotherapy. this method of
therapy is used for cancer (Hsueh and Morton 2003),
leishmaniasis (Carrero Rangel et al. 2011), autoimmune
disorders(Adorini and Sinigaglia 1997; Liu 2003) and
allergy (Yazdanbakhsh et al. 2002). Furthermore DNA
vaccines are used not only for prophylaxis, but also for
successful immunotherapy (Liu 2003, 2011). Generally,
the objective of passive immunotherapy is to generate a
quick and momentary protection or to sedate the existing
state of disease, whilst immunization in active form will
induce immune system and produce immunologic memory
that results in a boost immune response to repeated expo-
sure to the same antigen (Boulter-Bitzer et al. 2007;
Casadevall 1996).
In early twentieth century, passive immunotherapy
practiced for treatment of different infectious diseases
(Casadevall 1996; Casadevall and Scharff 1994, 1995). By
widespread growth of drug resistant pathogens and
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difficulties that are faced in treatment of drug resistance
infections (Grogl et al. 1992; Hadighi et al. 2006; Hyde
2007; Safari et al. 2014, 2013), immunotherapy may be
considered as a good solution with fewer side effects
(Badaro et al. 2006; Convit et al. 1987, 1989; Genaro et al.
1996; van der Weiden et al. 1990). So in the last century
immunotherapy either passive or active forms have been
practiced for control and treatment of parasitic diseases
(Boulter-Bitzer et al. 2007; Chamond et al. 2002).
On the other hand, after controlling the parasitic dis-
eases especially in developed countries, a simultaneous
raise in frequency of cancer and allergy was observed. So it
was hypothesized that parasitic infections may have a role
in stimulation of immune system in favor of controlling
such diseases (Darani and Yousefi 2012). As an example
worm therapy has been presented for treatment and control
of asthma (Araujo et al. 2010; Falcone and Pritchard 2005)
and multiple sclerosis (Correale 2014; Fleming 2013). In
this review article, parasite immunotherapy has been dis-
cussed in terms of immunotherapy against parasitic infec-
tions and also in terms of using parasites for treatment of
other diseases.
Immunotherapy against parasitic infection
Leishmaniasis
Leishmaniasis is probably the parasitic disease with the
most practices of immunotherapy for its treatment. In 1939
Salles-Gomesi attempted the first trial of vaccination of
human against leishmaniasis using dead leishmanial pro-
mastigote preparation. He evaluated the effects of inocu-
lation of dermotropic Leishmania spp., killed by phenol, on
cutaneous leishmaniasis. He observed therapeutic effects of
suspension of dead leishmanial promastigote preparation
and suggested that this kind of vaccine may produces
protection against the infection (Genaro et al. 1996;
Mayrink et al. 2006).
Pessoa and his colleagues carried out the first vaccina-
tion trials against leishmaniasis in 1940s using suspension
of promastigotes that resulted in reduction of 80 % in
occurrence of the infection. Interestingly they recorded no
side effects and Montenegro skin test remained negative
after vaccination (Genaro et al. 1996). After that, Convit
et al., and Mayrink et al., returned to practice immuno-
therapy in localized cutaneous leishmaniasis with killed
promastigotes along with BCG and also in mucosal leish-
maniasis using killed promastigote whole antigen, with
cure rate of 76 % (Mayrink et al. 1992) to 94 % (Convit
et al. 1987), respectively.
Vaccination is one of the safer, most acceptable and
practical prophylactic method in American cutaneous
leishmaniasis, but it could be useful for treatment of
mucosal leishmaniasis in some cases too (Genaro et al.
1996). Despite the fact that these vaccines are recom-
mended, they are unspecified mixtures, difficult to stan-
dardize and the possibility of causing noxious local or
systemic unwanted effects, so it seems unlikely to be used
widespread (Badaro et al. 2006; Machado-Pinto et al.
2002).
As it is experimented, the combination of a single-strain
Leishmania amazonensis killed promastigote crude antigen
vaccine along with a half dose regimen of meglumine an-
timoniate is impressively efficacious for the treatment of
American cutaneous leishmaniasis (Machado-Pinto et al.
2002). Immunotherapy using crude preparations of Leish-
mania antigen, with or without Bacille Calmette-Gue´rin, is
recommended and practiced successfully in treatment of
mucosal leishmaniasis and dramatically showed healing in
some patients with the disease (Convit et al. 1987, 1989,
2003; Genaro et al. 1996; Mayrink et al. 1992).
Vaccine therapy with a combination of define antigen,
along with standard chemotherapy reported to be an
effective strategy for treatment of drug-refractory mucosal
leishmaniasis. This method also demonstrates mild sys-
temic adverse effects such as: fever, headache, malaise or
somnolence in the first administration. Local reactions of
injection site such as redness and edema may occur and is
similar to that of leishmanin skin-test induration, but vivid
granulomatous reactions are absent. Local reaction happens
in first, second and third dose of immunotherapy. Drug
refractory mucosal leishmaniasis has successfully treated
with antigens thiol-specifi antioxidant, Leishmania major
stress inducible protein-1, Leishmania elongation initiation
factor, and Leishmania heat shock protein-83, plus granu-
locyte–macrophage colony-stimulating factor (Badaro
et al. 2006).
The effective role of Leishmania whole antigen in
acceleration of healing of cutaneous leishmaniasis and
mucosal leishmaniasis and also it’s very lighter side effects
has been proven and documented (Convit et al. 1987, 1989,
2003). Side effects are mostly occurs when vaccine is used
together with BCG (Convit et al. 1987, 2003).
Immunotherapy is also well practiced for canine visceral
leishmaniasis. The fucose mannose ligand (FML)-vaccine
showed hopeful impact on treating visceral leishmaniasis
of asymptomatic dogs experimentally infected by Leish-
mania donovani and Leishmania chagasi. Also this vaccine
causes increase in CD8 lymphocytes percentage in
peripheral blood of dogs (Borja-Cabrera et al. 2004).
Fucose mannose ligand (Leishmania donovani FML)-
saponin vaccine causes increase in types and subtypes of
anti-FML antibodies in visceral leishmaniasis in experi-
mentally infected murine model. The delayed type of
hypersensitivity response against promastigote lysate
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(DTH) and the in vitro proliferative response of ganglion
cells against FML antigen also occurs. Also, decline in
liver parasitic load reported in 94.7 % of FML-vaccine
treated mice (Santos et al. 2003).
Immunotherapeutic effects of heat killed Leishmania
crude antigen along with live BCG are in association with
T cell responses through Th1 and production of IFNc. T
cell response through antigen-driven IFNc production
alone does not cause immunopathology in mucocutaneous
leishmaniasis. Therefore, stimulation of Th1 response in
patients with American cutaneous leishmaniasis does not
end with immunopathology (Cabrera et al. 2000).
In conclusion, the triumphant usage of immunotherapy
in treatment of cutaneous leishmaniasis made this method
as a good substitute for chemotherapy in single-lesion
cutaneous leishmaniasis which chemotherapy is not rec-
ommended due to occurrence of drug resistance and also in
severe infections such as diffuse cutaneous leishmaniasis
and/or leprosy/HIV and Leishmania co-infections (Genaro
et al. 1996). Upregulation of Th1 profile and also the
absence of Th2 response is responsible factor for being
resistance to Leishmania infection (Barral-Netto et al.
1995; Holaday et al. 1991; Verwaerde et al. 1999).
Immunotherapy is an effective, safe and inexpensive
method for treatment of cutaneous leishmaniasis of man
and visceral leishmaniasis in animals (Borja-Cabrera et al.
2004; Cabrera et al. 2000; Convit et al. 1987, 1989; Santos
et al. 2003).
Cryptosporidiosis
Protozoan parasite Cryptosporidium is causative agent of
cryptosporidial diarrhea in animals and human being
(Fayer 2009). Cryptosporidiosis is mostly in low preva-
lence (Jafari et al. 2014b; 2013; Jafari et al. in press)
benign infection of humans that typically lasts for two
weeks, but in some special conditions it became a hostile
disease. It is difficult to treat the infection in immuno-
compromised/immunosuppressed individuals including
patients who have HIV/AIDS or organ transplantation
(Fayer 2009).
Chemotherapy for cryptosporidiosis has limited efficacy
in the treatment of the infection and that made researchers
to develop admissible rationale for immunological studies
of Cryptosporidium with recombinant vaccine using live or
attenuated parasite (Santı´n and Trout 2009). Studies carried
out in animals illustrated effective impact of hyperimmune
bovine colostrum, paromomycin, and nitazoxanide in
therapy of Cryptosporidium infections (Fayer and Ellis
1993; Jenkins et al. 1999a; Perryman et al. 1999; Theodos
et al. 1998; Tzipori et al. 1994).
Passive and active immunotherapeutic methods are
fruitful strategies for immunization against
cryptosporidiosis (Boulter-Bitzer et al. 2007). Passive
immunotherapy with antibody for Cryptosporidium infec-
tion is a method of treatment that has been practiced
experimentally and clinically. Several studies on this sub-
ject have been initiated in last decades, namely on use of
hyperimmune or naturally immune bovine colostrum con-
taining colostral antibody, antibodies from chicken egg
yolk, monoclonal antibodies and antibodies from human -
plasma that administrated orally. Majority of studies have
applied oral administration method of treating or prophy-
laxis of this protozoan infection. Variety of antibody
preparations has been tested in animals and man and
showed some degree of effectiveness (Crabb 1998).
Anti-Cyptosporidium parvum antibodies in hyperim-
mune bovine colostrum possess remedial effect on cryp-
tosporidiosis. These antibodies distinguish sporozoite,
oocyst and merozoite antigens; also they recognize stage-
specific antigens. After incubation of hyperimmune anti-
body with sprozoites, they experience noticeable morpho-
logic alterations, defined by oncoming production and
release of sporozoite membranous surface antibody-antigen
complexes. The reaction makes infectivity of sprozoites to
be neutralized (Riggs et al. 1994).
In experimentally infected nude mice model, intestinal-
infection score decreases when treated with neutralizing
Table 1 Some known antigens of C. parvum, which is identified by
antibodies are suggested to play a role in host immune
response(Boulter-Bitzer et al. 2007)
Antigen Reference
Sporozoite and merozoite cell surface
protein
gp15/45/60(Cpgp40/15) (Cevallos et al. 2000;
Strong et al. 2000)
CP15 (Jenkins and Fayer 1995)




CP47 (Nesterenko et al. 1999)
Cpa135 (Tosini et al. 2004)
Microneme proteins
Gp900 (Petersen et al. 1992)
TRAP-C1 (Spano et al. 1998)
Cryptosporidium oocyst wall protein
family
COWP (Fayer et al. 2000)
Other potential antibody targets
against C. parvum antigens
CPS-500 (Riggs et al. 1999)
CP41 (Jenkins et al. 1999b)
100-kDa antigen of sporozoites (Bonnin et al. 1993)
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monoclonal antibodies (mAb 17.41). Neutralizing mono-
clonal antibodies directed to sporozoite and merozoite
surface antigens, nullify the infectivity of sporozoites
(Bjorneby et al. 1991), reduce oocyst shedding and lower
the infection score in gall bladder (Riggs et al. 1994).
Bovine immune colostrum reduces 50 % of intestinal
development score of C. parvum in mice (Jenkins et al.
1999a). Some known antigens of C. parvum, which is
identified by antibodies are available in Table 1.
A protection against cryptosporidiosis would be
achieved by developing a vaccine against Cryptosporidium
spp., and if done would have several useful effects, espe-
cially and most importantly on immunocompromised
patients that are at risk of developing chronic infection. It is
expressed that an acceptable approach in treatment of
Cryptosporidium infection in immunocompromised indi-
viduals is passive immunotherapy using antibodies
appointed against merozoites and/or sporozoites of C.
parvum, administrated into the gastrointestinal lumen
(Boulter-Bitzer et al. 2007; Petersen et al. 1992).
Malaria
Glycosylphosphatidylinositol (GPI) is a glycolipid antigen
of Plasmodium spp., induces the overproduction of TNF-a
and IL-1 and probably contributes to the malarial patho-
physiology such as severe cerebral malarial. GPI derived
from malaria parasite can be a good candidate to raise
monoclonal antibodies to, and consequently can neutralize
the toxicity of extracts of the parasite. Parasite origin GPI
can be used as a target for immunotherapeutic purposes and
may it would be a good solution for severe malaria
(Schofield et al. 1993).
Another and most novel immunotherapeutic method for
malaria and cancer is CTLA-4 blockade. Exhaustion of T
cells is a usual immunoevasion mechanism in neoplastic
tumors and chronic infections. T cell exhaustion recogni-
tion in malaria proposes a much needful and modern
therapeutic tactics for treatment of this horrible disease of
mankind. In melanoma immunotherapy, CTLA-4 blockade
is approved to be used in treatment of the tumor. This
method of therapy, illustrated a promising perspective for
therapy of cancer and chronic infections (Freeman and
Sharpe 2012).
Monoclonal Antibody 7H8 (mAb 7H8) is an IgM
monoclonal antibody, which is producing by the hybrid-
oma cell line, directed against a protein of Plasmodium
spp. This antibody also binds to Pf93 that is an antigen
unique to P. falciparum. MAb 7H8 is proper for immu-
nodiagnostic tests and immunotherapy of malaria of human
and other animals, which plasmodial-associated antigen
expresses in and contained reactive epitopes to the mono-
clonal antibody (Taylor 1991).
American trypanosomiasis
Developing vaccine against the infection is a difficult and
intricate task, because the parasite is able to induce a
variety of mechanisms to make host immune system unable
to eradicate the infection (Chamond et al. 2002; de Souza
et al. 2010). Immunotherapy can help to increase the
effectiveness of the anti-parasite drug and consequently
decreases the severity of chronic infections such as lethal
chagas’ disease (Kumar and Tarleton 2001; Tarleton et al.
2000).
A desirable immunotherapy against American trypano-
somiasis would encompasses such molecules that stimulate
lymphocytes to act in several concordant immune respon-
ses, including antibody secretion, cytotoxic activity to
trigger moieties of parasite and cytokines to modulate
immune response against parasite (Camargo 2009; Cha-
mond et al. 2002).
Trypanosoma cruzi expresses glycophosphoinositol
(GPI), which is a potential stimulator of production of
interleukin 12 (IL-12). During the Chagas’ disease IL-12,
and probably GPI, may induce NKT cells to effect a pro-
tective response. It is shown that NKT cells implicate in
protective immune responses against this pathogen (Duthie
et al. 2002; Wilson et al. 2002), and may be a future
candidate target in the immunotherapy of infection.
For effective immunotherapy against Trypanosoma
cruzi infection, the significance of polyclonal lymphocyte
responses straight after the infections and the inefficient
immune homeostasis they cause are the most limitations. It
is thought that if immunotherapy against Trypanosoma
cruzi comprises molecules that are capable of negating or
inactivating nonspecific immune responses, in that way
immune responses are capable to develop a durable
response in its’ victim (Chamond et al. 2002).
Toxoplasmosis
Toxoplasmosis is a benign infection of man and other
warm-blooded animals, caused by a zoonotic protozoan
Toxoplasma gondii, belonging to the phylum Apicomplexa
(Galvan-Ramirez M de et al. 2012; Zhou et al. 2011). The
prevalence rate of the infection is fairly high in most
populations (Jafari et al. 2012; Rasouli et al. 2014).
In animal model, transference of the spleen or serum and
lymph node cells of guinea pigs that became immune
against RH strain of Toxoplasma gondii can results in
partial protection of symptomatic infection in recipient
guinea pigs. The phenomenon is according to the reduction
of dissemination or multiplication of Toxoplasma from
initiation of inoculation spot to other different organs of
immunotherapy recipient. The same degree of partial
immunity against disseminated toxoplasmosis happen in
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animals received suspensions of cell, rich for immune T
cells. However the immune cells exposed to a monoclonal
antibody raised against guinea pig T cell along with com-
plement, lose their capability to transfer resistance (Pavia
1986).
Trichomoniasis
Trichomoniasis is an infection caused by Trichomonas
vaginalis which is the common cause of vaginitis
(Schwebke and Burgess 2004). Lactobacillus vaccine,
Solco Trichovac, has a therapeutic impact on trichomoni-
asis which is resulted of cross reaction of vaccine induced
antibodies with Trichomonas vaginalis. Therefore sero-
logical assessment of the cross reactivity between Tricho-
monas vaginalis and lactobacilli from Solcotrichovac
vaccine has failed to prove the idea (Gombosova et al.
1986).
The Solco Trichovac is a lactobacillus vaccine which
dramatically showed therapeutic effect on trichomoniasis.
The cure rate has been reported 90 % (Bonilla-Musoles
1984) and 80 % (Karkut 1984) in vaccine therapy.
Immunotherapy of trichomoniasis has some advantages
over metronidazole which are the prophylactic effect of
vaccine on patients about reinfection and recurrence (Bo-
nilla-Musoles 1984).
There is a report about metronidazole and immuno-
therapy resistant trichomoniasis in two cases, which the
parasites were persistent after a high dose of intravenous
metronidazole administration. In this case the immuno-
therapy using Lactobacillus was unsuccessful (van der
Weiden et al. 1990).
Schistosomiasis
Schistosoma spp., are flatworms and causative agent of
schistosomiasis, which is a parasitic disease with second
public health significance after malaria. The prevalence of
the disease is estimated over 200 million cases and
1,00,000 deaths, annually (Jenkins-Holick and Kaul 2013).
Granulomatous response against ova of Schistosoma,
which are trapped in the host liver, is responsible of sub-
sequent fibrosis. It is reported that administrating inter-
leukin 12 (IL-12) along with Schistosoma egg prevents the
formation of pulmonary granuloma. Administration of eggs
along with IL-12 results in partial inhibition of formation
of granuloma and therefore considerably reduces the tissue
fibrosis persuade by natural Schistosoma mansoni infec-
tion. This achievement is a sample of vaccination in which
the pathogenesis of infection is prevented, but not the
infection itself. This is happening by substitution of Th2
cytokine response, characteristic of Schistosoma infection
immune response, by Th1 which is induced by IL-12.
Vaccination with antigen plus IL-12 in the variety of
infections with tissue fibrosis can help to improve the
patient’s condition (Wynn et al. 1995).
Interleukin-13 has many functional similarities to IL-4
(de Vries 1998), and also it shares the same receptor sub-
units with IL-4. Therefore it has the same role in patho-
genesis of schistosomiasis. Treatment with IL-13 inhibitor
(sIL-13Ra2-Fc) remarkably reduces the formation of
hepatic fibrosis in mice when infected by S. mansoni
(Chiaramonte et al. 1999).
Treatment of experimentally infected mice by S. man-
soni with monoclonal antibody raised against IL-4 inhibits
the formation of granuloma in lung, but not formation of
hepatic granuloma. Anti-IL-4 treatment notably reduces the
collagen deposition of liver. IL-4 has a significant role to
induce Th2 response in mice infected with S. mansoni and
subsequently contributes to formation of hepatic fibrosis
(Cheever et al. 1994; Kaplan et al. 1998).
Parasite stages or parasite antigens as targets
for immunotherapy of cancer, multiple sclerosis
or asthma
Hygiene hypothesis
Prolonged co-existence of parasites, especially helminthes,
and their hosts has been co-evolved over many generations.
The majority of parasites are adapted to the specific hosts,
which resulted in reduction in pathogenesis and their better
survival. This adaptation has led to the establishment of a
specific immunological microenvironment. The later phe-
nomena support the adaptability of both the host and the
pathogen (Rzepecka and Harnett 2013).
During recent decades, reduction in exposure to variety
of microbial organisms (Falcone and Pritchard 2005; Jafari
et al. 2014a; Rzepecka and Harnett 2013) and absence of
the subsequent immune response against them are
responsible for the increase in occurrence of allergic dis-
ease, which is called Hygiene hypothesis. Although, the
hypothesis has been questioned by some authors, because
there are some evidences that suggest that some of the
microbial infections may be deteriorate allergic asthma
rather than subsiding (Falcone and Pritchard 2005;
Rzepecka and Harnett 2013).
Asthma
The epidemiological data supports that the hookworm of
human, Necator americanus, might ameliorate symptoms
of asthma in atopic individuals (Scrivener et al. 2001). Also
the human hookworm is famous for its immune-modula-
tory capacity (Falcone et al. 2004; Pritchard and Brown
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2001). Data from experimentation on mice models clearly
illustrated that parasitic worms and their products can
alleviate asthma-like disease (Rzepecka and Harnett 2013).
The progress of Trichinella spiralis Infection from acute
to the chronic phase shows increase in protective effects on
experimental allergic airway inflammation in animal
model. T regulatory cells may play substantial role in the
amelioration of experimental allergic airway inflammation
(Aranzamendi et al. 2013).
Studies have been suggested that there is a protective
impact of parasites in subtracting skin test reactivity and
also the alleviation of symptoms of asthma, especially in
schistosomal infections (Figueiredo et al. 2012). Addi-
tionally, there is support for causal relationship between
atopy and helminthic infections (Cooper 2004). Although
some believe that intestinal helminthic infections, namely
ascariasis and trichuriasis, are regulating the immune
response and suppress the atopy, but some other intestinal
helminthic infections have shown no effect or exacerbated
the atopic diseases (Figueiredo et al. 2012).
Multiple sclerosis
Epidemiological studies revealed that helminth infected
individuals are less likely to be affected by autoimmune
diseases such as multiple sclerosis (MS). The thesis has
been experimented in animal model of MS, asthma, type I
diabetes and colitis. It is been observed that helminthes
infected mice are resilient against the mentioned diseases.
Up to now, helminth therapy with Trichuris suis ova and
Necator americanus larvae have been trailed in MS.
Mostly, no adverse effects have been perceived associated
with helminth therapy. Studies suggest some helminth-
derived immunomodulatory molecules, which are capable
of altering immune responses and, hence, the term of
autoimmune diseases (Correale 2014).
Helminthic infections in MS patients modulate immune
responses through a retinoic acid-dependent pathway.
Retinoic acid concentrations are higher in MS patients
infected by helminthes comparing to healthy individuals
(Correale and Farez 2013).
Soluble products of T. suis suppress the synthesis of the
pro-inflammatory cytokines such as TNF-a, IL-12 and IL-
6. Also it has been demonstrated for soluble products of
other helminthes too. These attributes, along with upregu-
lation of expression of CXCL16 and OX40L that are
considered as a positive signals for polarization of Th2
cells, may allow soluble products of T. suis to guide
monocyte-derived dendritic cells to conduct polarization to
lower the inflammation at sites of the infection. On the
other hand, Trichuris suis glycans are crucial important for
their capability about suppressing the production of pro-
inflammatory chemokine and cytokine of dendritic cells
(Klaver et al. 2013).
Cancers
Following control of parasitic diseases in developed
countries a marked increase in incidence and mortality of
cancers was occurred (Oikonomopoulou et al. 2013; Vineis
and Wild 2014). So it was postulated that parasite some-
how interferes with the tumor growth. Although the
mechanisms of inhibitory effect of parasite on cancer
growth are not understood, but there are raising scientific
evidences to support this idea. In culture medium it has
been shown that some parasites or parasite products inhibit
the growth of cancer cells. Also it has been shown that
parasite or parasite antigens reduce tumor growth in the
experimental animals. Some of these studies were also
summarized in Table 2.
Concluding remarks
As a conclusion, immunotherapy has been practiced suc-
cessfully in most cases of parasitic infections (Genaro et al.
1996; Mayrink et al. 2006) and some other diseases such as
cancer (Noguchi et al. 2013; Tse et al. 2014; Weiner et al.
2012) and autoimmune (Adorini and Sinigaglia 1997; Van
Kaer 2004) disorders. This method has shown hopeful
remarks regarding treatment of leishmaniasis (Convit et al.
1987) and trichomoniasis (Bonilla-Musoles 1984). Also it
can partially reduce the pathogenesis of the infection and
improve the patient’s condition in cryptosporidiosis (Riggs
et al. 1994), schistosomiasis (Wynn et al. 1995), malaria
(Schofield et al. 1993) and American trypanosomiasis
(Kumar and Tarleton 2001). In severe cases of the malaria
(Schofield et al. 1993) and leishmaniasis (Convit et al.
1987, 1989), immunotherapy alone or beside chemother-
apy, would be a best strategy to reduce the pathophysiology
Table 2 Parasites with anticancer activities in experimental animals
Row Parasite References
1 Hydatid cyst (Berriel et al. 2013)
2 Toxocara canis (Darani et al. 2009)
3 Acantamoeba
castellani
(Pidherney et al. 1993)
4 Plasmodium
yoelli
(Chen et al. 2011)
5 Trypanosoma
cruzi




(Darani et al. 2009; Kim et al. 2007;
Miyahara et al. 1992)
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of the infection. Another aspect which made immuno-
therapy as a remarkable method of treatment is drug
resistance, which is increasing in parasitic infections. This
phenomenon results in ineffective or less effective che-
motherapy. In these cases, immunotherapy would benefit
the treatment (Badaro et al. 2006).
On the other hand, interestingly parasite stages and
parasite antigens are proposed for immunotherapy of
asthma (Rzepecka and Harnett 2013) or cancers (Darani
and Yousefi 2012), respectively. Inhibitory effects of some
parasites such as Toxoplasma gondii (Darani et al. 2009;
Kim et al. 2007; Shirzad et al. 2012), Hydatid cyst (Aref
et al. 2012; Yousofi Darani et al. 2012), Toxocara canis
(Darani et al. 2009) and Trypanosoma cruzi (Kallinikova
et al. 2006; Mel’nikov 2004) on tumor growth has been
shown in culture medium or animal model. So immuno-
therapy with parasitic antigens may be an interesting line of
research in the future.
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